Patents by Inventor BRIAN A. ELENBAAS

BRIAN A. ELENBAAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predictive biomarker for hypoxia-activated prodrug therapy
    Patent number: 10760130
    Abstract: Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 1, 2020
    Assignee: MOLECULAR TEMPLATES, INC.
    Inventors: Brian A. Elenbaas, Antonio Gualberto, Charles Praray Hart
  • PREDICTIVE BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUG THERAPY
    Publication number: 20180334716
    Abstract: Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.
    Type: Application
    Filed: November 18, 2015
    Publication date: November 22, 2018
    Inventors: Brian A. Elenbaas, Antonio Gualberto, Charles Praray Hart
  • Predictive biomarker for hypoxia-activated prodrug therapy
    Patent number: 10071109
    Abstract: CYP2W1 levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of a hypoxia-activated achiral phosphoramidate mustards.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: September 11, 2018
    Assignee: Molecular Templates, Inc.
    Inventors: Brian A. Elenbaas, Lei Shen
  • PREDICTIVE BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUG THERAPY
    Publication number: 20160250236
    Abstract: CYP2W1 levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of a hypoxia-activated achiral phosphoramidate mustards.
    Type: Application
    Filed: October 28, 2014
    Publication date: September 1, 2016
    Applicant: MERCK PATENT GMBH
    Inventors: Brian A. Elenbaas, Lei A. Shen
  • TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTIVATED PRODRUG AND A TAXANE
    Publication number: 20160158253
    Abstract: Combined administration of a hypoxia-activated prodrug, such as TH-302, a taxane, such as nab-paclitaxel, and a nucleoside analog chemotherapeutic, such as gemcitabine, are efficacious in the treatment of cancer, including pancreatic cancer.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 9, 2016
    Inventors: CHARLES P. HART, JESSICA D. SUN, BRIAN A. ELENBAAS, ANTONIO GUALBERTO
  • Antibodies to the Human Prolactin Receptor
    Publication number: 20090017044
    Abstract: This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.
    Type: Application
    Filed: April 30, 2008
    Publication date: January 15, 2009
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Brian Elenbaas, Matthew B. Jarpe, Steven D. Miklasz, Stephen E. Fawell
  • Antibodies to the human prolactin receptor
    Patent number: 7422899
    Abstract: This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: September 9, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Brian Elenbaas, Matthew B Jarpe, Steven D. Miklasz, Stephen E. Fawell
  • Antibodies to the Human Prolactin Receptor
    Publication number: 20070269438
    Abstract: This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.
    Type: Application
    Filed: October 4, 2006
    Publication date: November 22, 2007
    Inventors: Brian Elenbaas, Matthew Jarpe, Steven Miklasz, Stephen Fawell